Despite their rapid growth, are there signs of this momentum slowing down towards the end of the decade? This webinar explores the headwinds that could impact the sector, such as the IRA and commercial pressures, as well as the influence of R&D success across big diseases.
Featuring Melanie Senior, the author of Evaluate’s Orphan Drugs report, Jeremy M. Levin, CEO of Ovid Therapeutics, and Andreas Hadjivasiliou, Managing Analyst at Evaluate, this discussion covered:
- The potential impact of the IRA on rare diseases and orphan drugs
- The size of the orphan drug market and key areas of growth
- Key players in the market
- The state of the orphan drug pipeline